Evidence map›Paper›PMID 28853905›Full record

ArticleAmerican journal of respiratory and critical care medicine2018

Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.

Deepika Polineni, Hong Dang, Paul J Gallins, Lisa C Jones, Rhonda G Pace, Jaclyn R Stonebraker, Leah A Commander, Jeanne E Krenicky, Yi-Hui Zhou, Harriet Corvol and 10 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00037765 active not recruitingnot on this map

Gene Modifiers of Cystic Fibrosis Lung Disease

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2001 to 2027Enrolled600ConditionsCystic Fibrosis, Lung Diseases
NCT01116414 completednot on this map

Molecular Phenotypes for Cystic Fibrosis Lung Disease

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2009 to 2023Enrolled152ConditionsCystic Fibrosis, Lung Diseases
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes.International journal of molecular sciences · 2022
    Review
  11. Article
  12. The proteostatic network chaperome is downregulated in F508del homozygote cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2021
    Article
  13. Article
  14. Article
  15. Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis.American journal of respiratory and critical care medicine · 2020
    Article
  16. Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2020
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 3 countries.

Deepika Polineni1 Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas.
Hong Dang2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.
Paul J Gallins3 Bioinformatics Research Center, Department of Biological Sciences.
Lisa C Jones2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.
Rhonda G Pace2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.
Jaclyn R Stonebraker2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.
Leah A Commander2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.
Jeanne E Krenicky4 Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Yi-Hui Zhou3 Bioinformatics Research Center, Department of Biological Sciences.
Harriet Corvol5 Pediatric Pulmonary Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Trousseau, Institut National de la Santé et la Recherche Médicale (INSERM) U938, Paris, France.
Garry R Cutting7 McKusick-Nathans Institute of Genetic Medicine.
Mitchell L Drumm4 Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Lisa J Strug9 Program in Genetics and Genome Biology.
Michael P Boyle11 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Peter R Durie12 Physiology and Experimental Medicine Research Program, and.
James F Chmiel4 Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Fei Zou15 Department of Biostatistics, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Fred A Wright16 Department of Statistics, and.
Wanda K O'Neal2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.
Michael R Knowles2 Cystic Fibrosis/Pulmonary Research and Treatment Center, Marsico Lung Institute, School of Medicine, and.
Lung Institute · USRainbow Babies & Children's Hospital · US3M (United States) · USInserm · FRJohns Hopkins University · USNorth Carolina State University · USPediatrics and Genetics · USUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA

Funding

Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Richard Charles Boucher, Martina Gentzsch · 2004 to 2026
$26.5M
Gene Modifiers in CF Lung DiseaseR01HL068890 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KNOWLES, MICHAEL R · 2001 to 2014
$9.5M
Molecular Phenotypes for Cystic Fibrosis Lung DiseaseR01HL095396 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KNOWLES, MICHAEL R, WRIGHT, FRED A. · 2008 to 2011
$2.9M
Permutation Approximations for Next Generation AssociationR21HG007840 · NHGRI · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI ZHOU, YIHUI · 2015 to 2016
$417k
CIHR MOP258916NHGRI NIH HHS R21 HG007840NHLBI NIH HHS R01 HL068890NHLBI NIH HHS R01 HL095396NIDDK NIH HHS P30 DK065988
6 · The paper itself

Abstract

rationaleThe severity of cystic fibrosis (CF) lung disease varies widely, even for Phe508del homozygotes. Heritability studies show that more than 50% of the variability reflects non-cystic fibrosis transmembrane conductance regulator (CFTR) genetic variation; however, the full extent of the pertinent genetic variation is not known.

objectivesWe sought to identify novel CF disease-modifying mechanisms using an integrated approach based on analyzing "in vivo" CF airway epithelial gene expression complemented with genome-wide association study (GWAS) data.

methodsNasal mucosal RNA from 134 patients with CF was used for RNA sequencing. We tested for associations of transcriptomic (gene expression) data with a quantitative phenotype of CF lung disease severity. Pathway analysis of CF GWAS data (n = 5,659 patients) was performed to identify novel pathways and assess the concordance of genomic and transcriptomic data. Association of gene expression with previously identified CF GWAS risk alleles was also tested. MEASUREMENTS AND MAIN

resultsSignificant evidence of heritable gene expression was identified. Gene expression pathways relevant to airway mucosal host defense were significantly associated with CF lung disease severity, including viral infection, inflammation/inflammatory signaling, lipid metabolism, apoptosis, ion transport, Phe508del CFTR processing, and innate immune responses, including HLA (human leukocyte antigen) genes. Ion transport and CFTR processing pathways, as well as HLA genes, were identified across differential gene expression and GWAS signals.

conclusionsTranscriptomic analyses of CF airway epithelia, coupled to genomic (GWAS) analyses, highlight the role of heritable host defense variation in determining the pathophysiology of CF lung disease. The identification of these pathways provides opportunities to pursue targeted interventions to improve CF lung health.

Indexed as

Genetic VariationAdolescentAdultCohort StudiesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDisease ProgressionFemaleGene Expression ProfilingGene Expression RegulationGenome-Wide Association StudyGenomicsHumansLung DiseasesMaleNasal MucosaCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorRNAcystic fibrosisepitheliagenomegenome-wide association studytranscriptome

Identifiers

PMID28853905
PMCPMC5765386
OpenAlexW2751826154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.